文献速递免疫规划

mRNA-1273而非BNT162b2诱导针对mRNA疫苗制剂中聚乙二醇(PEG)的抗体

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
PubMed 文献 · Vaccine · 2022-09-15

本研究采用酶联免疫吸附试验(ELISA)检测mRNA-1273与BNT162b2接种者血清中针对聚乙二醇(PEG)的抗体。结果显示,仅mRNA-1273接种者血清对mRNA疫苗制剂的反应性呈初免-加强依赖方式升高,且与抗PEG抗体水平相关;未发现PEG抗体与不良反应有明显关联。

要点

  • mRNA-1273接种者血清对mRNA疫苗制剂的反应性呈初免-加强依赖方式升高,BNT162b2接种者未见此现象。
  • 该反应性与抗高分子量及低分子量PEG抗体水平良好相关。
  • 基于疫苗相关副作用选择的血清中,PEG抗体与不良反应无明显关联。

核心结论

  • mRNA-1273与BNT162b2对anti-PEG抗体的诱导存在差异。
  • mRNA-1273诱导的PEG反应性抗体的临床相关性及其与其他PEG化药物的潜在相互作用尚待探索。

研究设计与样本

  • 研究采用酶联免疫吸附试验(ELISA)检测mRNA-1273或BNT162b2接种者血清中PEG特异性抗体反应。
  • 血清样本来自根据接种后疫苗相关副作用(包括迟发型、注射部位或严重过敏反应)选择的参与者。

主要发现

  • mRNA-1273接种者血清对mRNA疫苗制剂的反应性呈初免-加强依赖方式升高,BNT162b2接种者血清未见升高。
  • 对来自流感病毒mRNA制剂的无关脂质纳米颗粒观察到相同模式的反应性。
  • 此类抗体的反应性与针对高分子量和低分子量PEG的抗体水平良好相关。
  • 基于疫苗相关副作用选择的血清中,PEG抗体与不良反应无明显关联。

局限性

  • mRNA-1273疫苗诱导的PEG反应性抗体的临床相关性尚待探索。
  • 这些抗体与其他PEG化药物的潜在相互作用尚待探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Two messenger RNA (mRNA)-based vaccines are widely used globally to prevent coronavirus disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids in their composition, in the form of polyethylene glycol [PEG] 2000 dimyristoyl glycerol for mRNA-1273, and 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide for BNT162b2. It is known that some PEGylated drugs and products for human use which contain PEG are capable of eliciting immune responses that lead to to detectable PEG-specific antibodies in serum. In this study, we determined if any of the components of mRNA-1273 or BNT162b2 formulations elicited PEG-specific antibody responses in serum by enzyme linked immunosorbent assay (ELISA). We detected an increase in the reactivity to mRNA vaccine formulations in mRNA-1273 but not BNT162b2 vaccinees' sera in a prime-boost dependent manner. Furthermore, we observed the same pattern of reactivity against irrelevant lipid nanoparticles from an influenza virus mRNA formulation and found that the reactivity of such antibodies correlated well with antibody levels against high and low molecular weight PEG. Using sera from participants selected based on the vaccine-associated side effects experienced after vaccination, including delayed onset, injection site or severe allergic reactions, we found no obvious association between PEG antibodies and adverse reactions. Overall, our data shows a differential induction of anti-PEG antibodies by mRNA-1273 and BNT162b2. The clinical relevance of PEG reactive antibodies induced by administration of the mRNA-1273 vaccine, and the potential interaction of these antibodies with other PEGylated drugs remains to be explored.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Carreño JM, Singh G, Tcheou J, et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine. 2022. PMID: 36115801. doi:10.1016/j.vaccine.2022.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。